Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.32 |
| ▸ | NPY4R | P50391 | 2/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798538 | 1.00 | FAP (0.40) | FAPPDFSSTR3HRH1FURIN | |
| SCHEMBL17798539 | 1.00 | FAP (0.40) | FAPPDFSSTR3HRH1FURIN | |
| SCHEMBL32667900 | 0.94 | FAP (0.36) | FAPPDFSSTR3HRH1FURIN | |
| SCHEMBL28957936 | 0.91 | FAP (0.40) | FAPPDFSSTR3HRH1FURIN | |
| Bicarbonate SCHEMBL30831347 | 0.89 | FAP (0.42) | FAPPDFSSTR3FURINKMT2A | |
| SCHEMBL16279551 | 0.88 | MEN1 (0.34) | HRH1MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16279555 | 0.88 | MEN1 (0.34) | HRH1MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL20184659 | 0.85 | FAP (0.45) | FAPPDFSSTR3ALDH1A1L3MBTL1 | |
| SCHEMBL15676509 | 0.85 | FAP (0.45) | FAPPDFSSTR3ALDH1A1L3MBTL1 | |
| SCHEMBL29558207 | 0.85 | FAP (0.38) | FAPPDFSSTR3FURINMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | FAP 4180/4885PDF 1531/4885SSTR3 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.